Inhibrx Biosciences, Inc.INBXNASDAQ
Loading
Cost of Revenue Over TimeContracting
Percentile Rank22
3Y CAGR-71.8%
5Y CAGR-49.2%
Year-over-Year Change
Direct costs attributable to producing goods sold
3Y CAGR
-71.8%/yr
vs +34.7%/yr prior
5Y CAGR
-49.2%/yr
Recent deceleration
Acceleration
-106.5pp
Decelerating
Percentile
P22
Within normal range
vs 5Y Ago
0x
Contraction
Streak
2 yr
Consecutive growthContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $2.48M | +8.7% |
| 2024 | $2.29M | +91.9% |
| 2023 | $1.19M | -98.9% |
| 2022 | $110.19M | +3999.2% |
| 2021 | $2.69M | -96.3% |
| 2020 | $73.50M | +53.4% |
| 2019 | $47.91M | +43.2% |
| 2018 | $33.45M | +31.1% |
| 2017 | $25.51M | +50.1% |
| 2016 | $16.99M | - |